drugset
drugset / Trial / NCT06370754

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

NCT06370754 ↗

Phase 1/2 Not yet recruiting 117 enrolled Fudan University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of different novel immunotherapies in patients with advanced pancreatic cancer.

Timeline

Start
2024-04-30
Primary completion
2026-04-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject JS007 Unknown 3 mg/kg Intravenous
Subject JS015 Unknown 600 mg Intravenous
Subject Tifcemalimab Monoclonal antibody 200 mg Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Irinotecan Small molecule 60 mg/m2 Intravenous
Background Irinotecan Small molecule 70 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Paclitaxel Small molecule 125 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

malignant pancreatic neoplasm